Welcome to our dedicated page for AN2 Therapeutics SEC filings (Ticker: ANTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AN2 Therapeutics (NASDAQ: ANTX) sits at the intersection of cutting-edge infectious-disease science and high-stakes clinical milestones. Whether you are monitoring cash runway for its epetraborole program or gauging management confidence through share purchases, every SEC document carries market-moving clues.
Stock Titan brings these clues forward. Our AI-powered engine scans each AN2 Therapeutics annual report 10-K, quarterly earnings report 10-Q filing, and 8-K material event within seconds, translating dense biotech language into clear, decision-ready takeaways. Looking for AN2 Therapeutics insider trading Form 4 transactions? You’ll receive real-time alerts the moment an executive files. Need the latest status on patient enrollment? The relevant table from the AN2 Therapeutics earnings report filing analysis is highlighted for you.
Here’s what you can uncover:
- Cash burn trends and partnership revenue inside the AN2 Therapeutics annual report 10-K simplified
- Dose-response data updates in each AN2 Therapeutics quarterly earnings report 10-Q filing
- Trial read-outs or FDA designations via AN2 Therapeutics 8-K material events explained
- Board option grants through AN2 Therapeutics executive stock transactions Form 4
- Leadership pay packages within the AN2 Therapeutics proxy statement executive compensation
Our platform doesn’t stop at listing documents; it answers the questions professionals actually ask—like “understanding AN2 Therapeutics SEC documents with AI” or “how to interpret ANTX’s Phase 2 cost disclosures.” Skip the 200-page PDFs and move straight to insight with concise AI summaries, expert context, and Form 4 insider transactions real-time feeds—all updated the instant ANTX hits EDGAR.
AN2 Therapeutics (ANTX) reported interim results showing continued clinical progress and a tighter cash position. Total cash, cash equivalents and investments were $71.2 million as of June 30, 2025, with cash and cash equivalents of $18.22 million and short- and long-term investments of $44.70 million and $8.30 million, respectively. Management believes these resources are sufficient to fund the company’s current operating plan for at least 12 months.
The company recorded a $17.1 million net loss for the six months ended June 30, 2025 (versus $31.1 million in the comparable 2024 period), driven by research and development and general and administrative expenses. AN2 advanced AN2-502998 into Phase 1 start-up activities and completed dosing of the first single ascending dose cohort (reported events in May and August 2025). Funding arrangements include government and foundation awards, but a NIAID contract was reduced by $9.0 million to a cumulative $9.3 million commitment. The company continues to rely on external financing and grants while it advances multiple boron-chemistry programs.
AN2 Therapeutics reported that it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference into this Form 8-K. The filing states that the information in Item 2.02 and Item 9.01 (including Exhibit 99.1) is furnished and shall not be deemed "filed" under Section 18 of the Exchange Act, and will not be incorporated by reference in other filings except by specific reference. The report is dated August 12, 2025 and is signed by Chief Executive Officer Eric Easom.
AN2 Therapeutics, Inc. (ANTX) filed a Form 4 reporting a routine equity grant to director Kabeer Aziz. On 07/10/2025 Mr. Aziz received 11,875 shares of common stock issued in lieu of cash compensation under the company’s non-employee director compensation policy. Because the award was compensation, the shares were priced at $0.00 and vested immediately.
Following the grant, Mr. Aziz now directly holds 30,552 shares. He also has indirect beneficial ownership—through Adjuvant Global Health Technology Fund, L.P. (1,995,958 shares) and Adjuvant Global Health Technology Fund DE, L.P. (377,542 shares)—bringing total reported influence to roughly 2.404 million shares. However, the filing notes that voting and dispositive power is shared with the funds’ general partners and that beneficial ownership is disclaimed except for pecuniary interest.
No derivative securities, options, sales, or open-market purchases were reported, and no cash was exchanged. The transaction appears purely compensatory and does not signal a deliberate insider buy or sell decision. Investors typically view such awards as neutral unless the size represents a material percentage of total shares outstanding, which the filing does not disclose.
FAQ
What is the current stock price of AN2 Therapeutics (ANTX)?
What is the market cap of AN2 Therapeutics (ANTX)?
